Drug intelligence / Profile preview

CGT-9475

Development stage: Unknown
Lead developer: CGeneTech
Modality: Small Molecules
Administration: Oral

Overview

CGT-9475 is an investigational **small molecule** **oral ALK inhibitor** being developed by **CGeneTech** for **ALK-positive non-small cell lung cancer**. Company and trial descriptions characterize it as a next-generation anaplastic lymphoma kinase inhibitor intended to address key treatment challenges such as **acquired resistance** and **brain metastases** in patients with locally advanced or metastatic disease. Publicly available information indicates development in an early clinical setting, with a Phase I/IIa dose-escalation study evaluating safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase II dose in ALK-positive advanced lung cancer.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on CGT-9475.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGT-9475.

Explore the full profile